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SCREENING LEAD SMALL MOLECULES FOR CYTOKINE INDUCTION IN A 
HUMAN WHOLE BLOOD ASSAY INFORMS CANDIDATE ADJUVANT 
SELECTION 
TANZIA SHAHEEN 
ABSTRACT 
Background: The human immune system is comprised of various cells that function to 
fight infection while also avoiding harmful inflammatory and autoimmune responses. 
The immune system consists of the innate and adaptive immune responses. While the 
adaptive immune response is involved in the late phase of infection and plays a role in 
generating classic T and B-cell based immunological memory, the innate immune 
response is the first line of defense and plays a role in early recognition of foreign 
substances and induction of an inflammatory response. Although the innate immune 
response is a natural and inborn response, it varies with age. Human newborns in 
particular are immunologically distinct due to their polarized T helper type 2 (Th2) cell 
response and increased anti-inflammatory cytokine production. While these adaptations 
protect the fetus from rejection by the mother, they lead to increased susceptibility of 
newborns to infection. While immunization is the most promising strategy to combat this 
increased susceptibility of newborns, the responses of newborns to different vaccines are 
impaired as a result of their functionally distinct immune system. For this reason, there 
have been efforts to develop and incorporate adjuvants into vaccines in order to enhance 
the immune response of newborns and young infants, who suffer the greatest burden of 
infectious diseases.  
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Objective: The objective of this thesis is to determine which compound(s) in a small 
molecule library (compound 037 family) that had been identified based on a high 
throughput TNF-α screen of human primary mononuclear cells activates immune cells 
and has the potential to act as effective vaccine adjuvants.  
Methods: Human cord blood was collected from 7 healthy term newborns after Cesarean 
section and peripheral blood was collected from the arms of 15 healthy adult volunteers 
between the ages of 18 and 60. The blood was processed and the compounds of the small 
molecule library were tested via whole blood assays and enzyme-linked immunosorbent 
assays (ELISAs) to measure production of pro-inflammatory cytokines, specifically 
tumor necrosis factor (TNF) and interleukin-1β (IL-1β). The responses of the compounds 
were further characterized by measuring additional cytokines and chemokines via a 41-
plex cytokine multiplex assay.  
Results: It was determined that at the top two concentrations that were tested (3.7 µM 
and 11.0 µM), certain compounds of the 037 family induced TNF and IL-1β production 
comparable to that produced by R848, an already established adjuvant. The compounds 
with the most activity depended on which cytokine was being produced as well as the age 
group (newborn vs. adult). Results of the 41-plex cytokine multiplex showed that while 
there is no clear indication of which group of cytokines are produced after stimulation 
with these compounds, there was increased production of certain chemokines, especially 
in adults.  
Conclusions:  The difference in activity of the compounds in the 037 family suggests 
that the functional groups might play a role in enhancing activity of certain compounds. 
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The increased production of chemokines after stimulation with these compounds suggests 
that the compounds might activate pathways different from TLR7/8 but still results in an 
inflammatory response. More work needs to be done in order to identify the receptors and 
pathways that these compounds activate.  
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INTRODUCTION 
The Human Innate Immune System 	  The human immune system is comprised of many different cells that are 
designed to protect the host against infection while also avoiding harmful inflammatory 
and autoimmune responses (Dowling & Levy, 2014). The immune system consists of the 
innate immune response and the adaptive immune response. While the adaptive immune 
response is involved in the elimination of pathogens in the late stage of infection as well 
as generation of immunological memory, the innate immune system is the first line of 
defense against infection, and is involved in early recognition of pathogens as well as 
induction of a pro-inflammatory response (Mogensen, 2009). The innate immune 
response is a nonspecific response that is primarily mediated by phagocytic cells and 
antigen-presenting cells (APCs), including granulocytes, dendritic cells, and 
macrophages (Mogensen, 2009). The functions of the innate immune system can be 
broken up into three categories, namely sensor, effector, and regulatory, in which 
activation of the sensor function leads to downstream activation of the effector and 
regulatory functions (Kollmann, Levy, Montgomery, & Goriely, 2012). One of the best 
known sensors of the innate immune system are pattern recognition receptors (PRRs), 
that function to detect different pathogens, including bacteria, fungi, parasites, and 
viruses (Garand, Cai, & Kollmann, 2017). Innate immune cells use these PRRs to 
recognize specific pathogen-associated molecular patterns (PAMPs) on the pathogens 
(Shey et al., 2014). PAMPs are structures that are evolutionarily conserved and do not 
vary among classes of pathogens. PAMPs are necessary for the survival of the pathogen 
		 2 
(Mogensen, 2009). Specialized subsets of innate immune cells called antigen-presenting 
cells (APCs) can activate cells of the adaptive immune system to induce cellular and 
humoral immune responses after activation through PRRs (van Haren, Ganapathi, et al., 
2016). Of the pattern recognition receptors, the toll-like receptors (TLRs) are most 
studied and are expressed on hematopoietic cells, where they work to recognize patterns 
of different microbial products and then signal the cells to elicit the appropriate response 
(Takeda & Akira, 2001). The responses vary, but can include phagocytosis, production of 
different cytokines, production of chemokines, which use chemotaxis to induce 
recruitment of different leukocytes such as neutrophils, and induction of the adaptive 
immune system (Shey et al., 2014).  
Modern Vaccine Development - Adjuvants and their Role in Activating PRRs 
 Modern vaccines induce an adaptive immune response to an antigen by 
mimicking the naturally occurring immune response to the pathogen-associated antigen 
without actually causing disease (Vasou, Sultanoglu, Goodbourn, Randall, & Kostrikis, 
2017). The induction of the innate immune response and the activation of the specialized 
APCs by the vaccine eventually result in a pathogen-specific adaptive immune response 
(Vasou et al., 2017). Although vaccines provide many benefits, there are limitations. 
Many vaccines that contain purified protein antigens usually result in a weak antibody 
response, or may require multiple immunizations in order to induce a sufficient antibody 
response (Reed, Orr, & Fox, 2013). Because of this, there have been efforts to improve 
the efficacy of vaccines through the use of molecules known as adjuvants. Adjuvants are 
defined as substances that have the ability to enhance antigen-specific immune responses 
		 3 
(Mims, Nash, & Stephen, 2001). Adjuvants may be included in vaccines in order to 
enhance the response to the antigens, lower the doses needed for a sufficient response, or 
both (Mims, Nash, & Stephen, 2001). Reed et al. (2013) created a diagram outlining the 
potential benefits of incorporating adjuvants into vaccines (Figure 1).  
 
Figure 1. Potential Benefits of the Use of Adjuvants in Vaccines. In this figure, the 
potential beneficial impact of adjuvants and the ways in which they can fill in the gaps in 
modern vaccine development are outlined (Reed et al., 2013).  
 
As previously mentioned, PRRs serve as the bridge between the innate and adaptive 
immune responses because they are required for the activation of APCs, which eventually 
result in the induction of a pathogen-specific adaptive immune response. For this reason, 
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PRRs are potential targets for adjuvant development (Vasou et al., 2017). More 
specifically, TLR agonists are targets for adjuvant development because TLRs induce 
pro-inflammatory cytokine/chemokine production, which increases the host’s ability to 
eliminate the pathogen (Steinhagen, Kinjo, Bode, & Klinman, 2011). Currently, there are 
licensed vaccines that contain pure TLR agonists.  One such vaccine is Cervarix which is 
used for the protection against human papillomavirus (HPV), which is a leading cause of 
cervical cancer (Monie, Hung, Roden, & Wu, 2008). This vaccine consists of HPV16 and 
HPV18 L1 (capsid protein) virus-like particles and is formulated in ASO4 adjuvant. The 
ASO4 adjuvant is comprised of alum (aluminum salts) in combination with a TLR4 
ligand called MPL (3-O-desacyl-4’-monophosphoryl lipid A) (Monie et al., 2008). 
Another example of a currently licensed vaccine that uses a pure TLR agonist is 
Heplisav, which is a vaccine for the Hepatitis B virus. Hepsilav consists of the hepatitis B 
surface antigen (HBsAg) and 1018, which is a short oligonucleotide sequence with CpG 
motifs (Campbell, 2017). The unmethylated CpG sequences stimulate the innate immune 
system via activation of TLR9 (Campbell, 2017).  
 The use of adjuvants in vaccines, particularly the ones targeting different TLR 
pathways, is becoming increasingly important to improve the efficacy of different 
vaccines. As previously mentioned, vaccines are important for enhancing the immune 
response to different pathogens. The use of vaccines is especially important in 
immunocompromised individuals, such as human newborns. Though the innate immune 
response is a natural and inborn response in all humans, it still varies with age.  
		 5 
The Human Newborn Innate Immune System is Functionally Distinct, Leading 
to Impaired Immune Responses 
The fetus and newborn face a different set of environments both when intra-
uterine and after delivery, each with a different set of immunological demands. Normally, 
the fetus is protected from inflammation by the mother, leaving the fetus with a lack of 
stimuli that is needed for the immune system to become functionally mature (Sadeghi et 
al., 2007). While transitioning from a sterile intra-uterine environment to one that has 
many foreign antigens, the fetus must have mechanisms to protect against infection while 
also avoiding harmful inflammatory responses that can result in pre-term delivery (Levy, 
2007). Previous literature has shown that pro-inflammatory cytokines, such as tumor 
necrosis factor (TNF) and interleukin-1β (IL-1β), are linked to premature labor and pre-
term delivery of the newborn. There is also evidence that TNF is associated with 
spontaneous abortion due to the induction of apoptosis in both placental and fetal cells 
(Levy, 2007). Because of this, the innate immune system of human newborns is polarized 
towards an increased T helper type 2 (Th2) cell response with anti-inflammatory cytokine 
production, while having a decreased T helper type 1 (Th1) cell response with pro-
inflammatory cytokine production (Dowling et al., 2017). These adaptations protect the 
fetus from rejection by the mother, allows for microbial colonization, and protects the 
fetus from an excess of pro-inflammatory responses (Saso & Kampmann, 2017). 
However, this polarization of the innate immune response increases the susceptibility of 
newborns to infection, while also impairing their responses to different vaccines (Levy, 
2007). More specifically, this polarization of the innate immune response leads to a 
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reduced function of dendritic cells, which are important APCs. This results in a 
suboptimal vaccine-induced Th1 immune response, putting newborns at higher risk of 
infection by intracellular pathogens (van Haren, Dowling, et al., 2016). This poses a 
major health care issue, with infection of newborns and infants resulting in an annual 
global mortality exceeding one million lives (Cuenca, Wynn, Moldawer, & Levy, 2013). 
Because of this, there have been efforts to prevent neonatal infection through the use of 
different adjuvants and vaccines.  
The Role of Adjuvants in Aiding the Newborn Innate Immune System Response 
 Immunization of the human newborn is an important strategy to combat the issues 
of morbidity and mortality that result in response to infection in early life (Saso & 
Kampmann, 2017). However, as previously mentioned, newborn responses to different 
vaccines are impaired due to their functionally distinct innate immune system. Vaccine-
induced responses result in slow initiation of a response, low immunogenicity, and 
decreased persistence of functional antibodies (Dowling et al., n.d.). This impaired 
immune response is due to a low precursor cell frequency and quantity in newborns, 
especially dendritic cells, which results in a suboptimal adaptive immune response 
(Basha, Surendran, & Pichichero, 2014). The need for improved vaccine immunogenicity 
in newborns has led to the ongoing efforts to enhance vaccines through the use of 
adjuvants. Given the promising nature of adjuvants and the role that they can play in 
vaccine development, there is ongoing research and efforts to incorporate different 
adjuvants in vaccines in order to shift the neonatal immune response towards the TH1 
cytokines, and enhance neonatal immunization overall. It has been shown that activation 
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of certain PRRs in newborns, such as TLRs 7/8, can result in an immune response similar 
to adults (Scheid et al., 2018). One such adjuvant is Resiquimod (R848), an 
imidazoquinoline molecule that has potent anti-viral activity (“Resiquimod - R848 | 
TLR7 and TLR8 Agonist | InvivoGen,” n.d.). R848 acts as a TLR 7/8 agonist that works 
to recruit and activate local immune cells, induce antigenic uptake by antigen-presenting 
cells (APCs), and initiate an adaptive immune response (van Aalst et al., 2018). When 
delivered with a vaccine, R848 has been shown to result in a Th1-polarized response (van 
Aalst et al., 2018). Studies have shown that monocytes and APCs collected from 
newborns and adults resulted in a greater Th1-response when induced by TLR8 
stimulation than compared to other TLR ligands (Steinhagen et al., 2011). TLR7/8 
ligands activate dendritic cells to enhance expression of co-stimulatory molecules and 
induce pro-inflammatory cytokine production, making TLR7/8 agonists potential targets 
for adjuvant and vaccine development (Steinhagen et al., 2011).  
Due to limited variety in existing adjuvants and their mechanism of action, the 
objective of this project was to identify novel vaccine adjuvants and determine their 
mechanism of action. In order to do this, ~200,000 compounds from a library of 
compounds were screened at the Harvard Medical School robotic screening core using a 
THP-1 monocytic cell line containing a human nuclear factor-kappa beta (NF-κB) 
luciferase reporter gene. If the compounds activated the NF-κB gene, luciferase enzyme 
was secreted, which could be quantified with a luminescent substrate. In addition, a 
phenotypic screen for adherence to the culture dish was included to identify compounds 
that are able to activate THP-1 cells in an NF-κB-independent fashion. A third arm of the 
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screen tested the compounds on primary human peripheral blood mononuclear cells 
(PBMCs) from healthy volunteers by detection of TNF secretion. This part of the screen 
identified one compound of interest, referred to as compound 037. This compound was 
able to induce TNF secretion by PBMCs, although it did not activate the NF-κB gene in 
THP-1 cells. This led to the identification and purchase and synthesis of close structural 
analogues of the parent compound 037 in order to determine which compounds have the 
most potential to act as an adjuvant. At this time, the compound structures and names 
cannot be included as they are the subject of a multi-year patent effort and we are not at 
liberty to reveal the structures at this time. However, in the Levy Lab the compounds are 
identified as follows: 037 (parent compound), 37.37, FRF-02-116, FRF-02-118, FRF-02-
144-3, FRF-02-166, FRF-02-167, FRF-02-169, FRF-02-171, and FRF-02-175.  
Testing of these different compounds may allow for the determination of new potential 
adjuvants that can be incorporated into vaccines, which can aid in overcoming 
susceptibility to infection for immune-compromised populations, including newborns.  
 
 
 
 
 
 
		 9 
SPECIFIC AIMS  
  The vulnerability of human newborns to infectious diseases is due to a 
suboptimal innate immune response (Smolen et al., 2014). Immunization is the best 
course of action to combat the susceptibility of human newborns to infections, but due to 
functionally distinct response to commonly used adjuvants, the newborn response to 
many vaccines may be suboptimal. This has led to the ongoing efforts to develop 
adjuvants that will enhance the efficacy of newborn vaccination. In this paper, we 
hypothesize that the compound of interest that was identified from the compound library 
discussed earlier, compound 037, can induce pro-inflammatory cytokine production, 
namely TNF and IL-1β. This hypothesis will be tested through the following Specific 
Aims:  
 Aim One: Test compound 037, as well as the different structural analogues of 
compound 037, via whole blood assays and ELISAs in order to determine the site of 
action of these compound as well as which compound(s) from this family is the most 
promising molecule for adjuvant development. This will be done by measuring the 
cytokines TNF and IL-1β as key pro-inflammatory cytokines.  
 Aim Two: Determine the age-specificity of these compounds with regards to their 
ability to stimulate immune cells by comparing newborn and adult cells.  
 Aim Three: Characterize further the nature of the response of the candidate 
adjuvant-induced innate immune response by measuring additional cytokines and 
chemokines via 41-plex cytokine multiplexing.  
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METHODS  
Ethics Statement  
 This study was conducted according to the principles outlined in the Good 
Clinical Practice Guidelines, and the Declaration of Helsinki. Collection of peripheral 
blood by adult healthy volunteers was approved by the Boston Children’s Hospital 
Institutional Review Board, and collection of cord blood from discarded material after 
ceasarian section was approved by the Brigham and Women’s Hospital Institutional 
Review Board.  
Study Population and Blood Samples  
Cord blood was collected from term newborns (n=7) immediately after cesarean 
section, and peripheral blood was collected from healthy adult volunteers (n=15), with an 
age range of 18-60 years old. Subjects that were HIV-positive or had any chronic medical 
condition or immune deficiency were excluded from this study. All blood draws were 
performed in a hospital setting by a trained phlebotomist. For the adult blood collection, 
the samples were collected from the arm. All blood samples were kept at room 
temperature and were processed within 4 hours of the blood draw.  
Preparation of Small Molecule Library  
The ten different compounds (037 family) as well as dimethyl sulfoxide (DMSO) 
and Resiquimod (R848), were used in this study. The ten compounds of the 037 family 
were dissolved in DMSO. Dimethylsulfoxide (DMSO) was purchased from Sigma. 
Resiquimod (R848) was purchased from Invivogen. Compounds 037 and 37.37 were 
purchased from Life Chemicals, and the remaining eight compounds were purchased 
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from Dana-Farber Cancer Institute. All twelve compounds were prepared 200x 
concentrated and serially diluted to the following concentrations: 11 micromolar (µM), 
3.7 micromolar (µM), 1.2 micromolar (µM), and 0.4 micromolar (µM).  
Whole Blood Assay 
Whole blood, collected either from term newborns or healthy adult volunteers, 
was diluted 1:1 (v/v) in RPMI 1640 medium (Gibco).  One microliter of each of the 
twelve different compounds was added to each well containing 200 microliters of diluted 
blood in a 96-well round-bottomed plate (Becton Dickinson (Falcon) at the final 
concentration as indicated.  The plate was then incubated in the presence of 5% CO2 at 
37oC in a humidified incubator for 18 hours. After 18 hours, supernatants were collected 
into a new 96-well round-bottomed plate (Falcon) using a multichannel pipette, without 
disturbing the cell pellet. Supernatants were stored at -80o until measurement of the 
concentration of secreted cytokines in response to the twelve different compounds.  
Cytokine Measurement via Enzyme-Linked Immunosorbent Assay (ELISA) 
 IL1β and TNF levels were measured by ELISA, purchased from Invitrogen 
(Carlsbad, CA). Corning Costar 9017 Medium Binding Capacity 96 well ELSIA plates 
(eBioscience) were used to measure TNF, and Corning Costar 9018 High Binding 
Capactiy 96 well ELISA plates (eBioscience) were used to measure IL1β. The plates for 
each cytokine were coated using the coating buffer and capture antibody provided in each 
ELISA kit. The capture antibodies, each 250x concentrated, were appropriately diluted in 
the coating buffer. 100 microliters of the coating buffer/capture antibody mixture were 
added to each well in the appropriate plate. The plates were then covered with ELISA 
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plate sealers (R&D Systems) and stored in a 4oC fridge overnight.  The next day, the 
Costar ELISA plates were taken out of the 4oC fridge and washed using a plate washer 
and wash buffer. The wash buffer was made from 10xPBS and distilled water, with 0.1% 
(v/v) TWEEN-20 added to it. The plates were then blocked by adding 200 microliters per 
well of the assay diluent, provided in the Invitrogen ELISA kits. The assay diluent was 
properly diluted using distilled water. After blocking, the plates were then covered with 
the plate sealers and incubated at room temperature for one hour. After one hour, the 
plate contents were discarded and the plates were washed again using the plate washer 
and wash buffer. The TNF standards (15 ng/mL stock concentration) were prepared by 
serially diluting 2-fold, starting with a top concentration of 1000 pg/ml down to 7.8125 
pg/ml using 1.5 mL tubes (Denville) and a vortex. Similarly, the IL1B standard (15 
ng/mL stock concentration) were prepared by serially diluting 2-fold, starting with a top 
concentration of 15 pg/ml down to 1.171875 pg/ml using 1.5ml tubes (Denville) and a 
vortex. 100 microliters of the prepared standards and blanks (assay diluent) were then 
added to each well of the first two columns of appropriate ELISA plates. The rest of the 
wells in each plate were filled with the appropriate amount of assay diluent and 
supernatant for a total of 100 microliters per well. The plates were then covered with the 
plate sealers and incubated at room temperature for two hours. After two hours, the plate 
contents were discarded and the plates were washed using the plate washer and wash 
buffer. The TNF and IL1B detection antibodies, each provided in the appropriate ELISA 
kit and each 250x concentrated, were appropriately diluted in the assay diluent. 100 
microliters of the assay diluent/detection antibody mixture were added to each well in the 
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appropriate ELISA plate. The plates were then covered with plate sealers and incubated 
at room temperature for one hour. After one hour, the plate contents were discarded and 
the plates were washed using the plate washer and wash buffer. Streptavidin-HRP 
(provided in the ELISA kits), which was 250x concentrated, was appropriately diluted in 
the assay diluent. 100 microliters of the streptavidin-HRP/assay diluent mixture was 
added to each well of the ELISA plates. The plates were then covered with the plate 
sealers and incubated in the dark for 30 minutes. After 30 minutes, the plate contents 
were discarded and the plates were washed using the plate washer and wash buffer. 100 
microliters of the TMB substrate reagent (Invitrogen) were added per well of each ELISA 
plate and allowed to develop until at least the top five standards were visibly blue, with 
the top standard as dark blue. Once the color change was visible, 100 microliters of stop 
solution (2N sulfuric acid) were added to each well. The plates were then read on an 
ELISA plate reader (VERSAmax microplate reader purchased from Molecular Devices) at 
450 nanometers. The values were obtained using the SoftMax Pro software. The 
concentrations of TNF and IL-1β were determined by intrapolation from a curve of the 
standard curve samples using nonlinear regression analysis.  
Cytokine Measurement via 41-plex Cytokine Multiplex 
 20 microliters of plasma was used to measure the concentration of different 
cytokines using a custom-designed multi-analyte Cytokine Human Magnetic Panel bead 
array, (Invitrogen/Life Technologies, Carlsbad; CA) consisting of: EGF, FGF-2, Eotaxin, 
TFG-alpha, G-CSF, Flt-3L, GM-CSF, Fractalkine, IFN alpha 2, IFN gamma, CXCL1, Il-
10, MCP-3, IL-12p40, MDC, IL-12p70, PDGF-AA, IL-13, PDGF-AB/BB, IL-15, 
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sCD40L, IL-17A, IL-1RA, IL-1 alpha, IL-9, IL-1β, IL-2, IL-3, IL-4, IL-5, Il-6, IL-7, IL-8 
(CXCL8), IP-10 (CXCL10), MCP1, MIP1 alpha, MIP-1 beta, RANTES, TNF-a, TNF-B, 
and VEGF. The following briefly outlines the steps involved, according to the 
manufacturer’s protocol. First, a 384-well plate was used, in which 20 microliters of the 
sample, standard, or kit-provided quality control sample was added to 20 microliters of 
assay buffer and 10 microliters of the bead mixture in each well. The plate was then 
mixed on a plate shaker for 18 hours at 4oC and 750 revolutions per minute (RPM). After 
18 hours, the beads were then washed 2 times using 50 microliters of wash buffer, which 
consisted of 10xPBS, distilled water, and 0.1% Tween-20. Then, 6 microliters of the 
detection antibody mixture provided by the kit was added to each sample in the plate. The 
plate was then incubated on a plate shaker for one hour at room temperature and 750 
RPM. After one hour, 6 microliters of streptavidin-phycoerythrin (Strep-PE) was added 
to each sample. The plate was then incubated for 30 minutes at room temperature on a 
plate shaker at 750 RPM. After 30 minutes, the plate was washed two times with the 
wash buffer. Then, 35 microliters of the PBS was added to each sample well. PE-
Fluorescence (wavelength = 578 nm) was measured using a Flexmap 3D system with 
Luminex xPONENT software version 4.2 (both from Luminex Corp., Austin, TX, USA). 
Cytokine concentrations were determined using the Milliplex Analyst Software (Version 
3.5.5.0, Millipore) by using a nonlinear regression analysis of the standard curve samples.  
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Statistical Analysis 
  The data for the ELISAs were graphed and statistically analyzed using GraphPad 
Prism version 7 software. The nonparametric Wilcoxon matched-pairs	signed	rank	test	was	performed	to	compare	the	activity	of	each	of	the	10	compounds	as	well	as	R848	to	DMSO	(unstimulated	condition).	The	repeated	measures	(RM)	2-way	ANOVA	was	performed	to	evaluate	the	potency	of	the	most	active	compounds.	The	Mann-Whitney	test	was	performed	to	compare	the	differences	in	activity	of	the	compounds	between	newborns	and	adults.	For	the	41-plex	cytokine	multiplexing,	the	data	was	also	graphed	and	analyzed	using	GraphPad	Prism	version	7	software.		
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RESULTS 
Description of the Study Population and Blood Collection 
 Peripheral whole blood was collected from 15 healthy adult volunteers between 
the ages of 18 and 60. Cord blood was collected from 7 term newborns, immediately after 
cesarean section. Subjects were excluded if they were HIV-positive or had any other 
significant chronic medical condition or immune deficiency.  
Cytokine Responses to Lead Adjuvant Candidates – Determination of Most 
Active Compounds  
 Ten different compounds (from the compound 037 family) were tested for 
induction of pro-inflammatory cytokines, specifically TNF and IL-1β. The compounds 
were tested in comparison to R848, which served as the positive control, as well as 
DMSO, which served as the unstimulated condition. Figures 2 and 3 below show that 
certain compounds induce pro-inflammatory cytokine production comparable to that 
produced by R848 in adults, while Figures 4 and 5 illustrate the compounds that induce 
pro-inflammatory cytokine production in newborns.  
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Figure 2. Lead Candidate Adjuvants Induce TNF Production in Human Adult 
Whole Blood Assay. The production of TNF in adult human whole blood after 
stimulation with the compounds of the 037 family, as well as DMSO and R848 (n=14; 
one of the adult data sets was excluded due to lack of TNF production in response to 
stimulation with R848) is shown. The compounds were tested at four different increasing 
concentrations, indicated by the black triangles. The concentrations are 0.4 µM, 1.2 µM, 
3.7 µM, and 11.0 µM. The stars indicate statistical significance between the indicated 
compound over the DMSO-treatment, as determined by running a nonparametric 
Wilcoxon matched-pairs rank test for each compound in comparison to the unstimulated 
condition (DMSO).  
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Figure 3. Lead Candidate Adjuvants Induce IL-1β  Production in Human Adult 
Whole Blood Assay. The production of IL-1β in adult human whole blood after 
stimulation with the compounds of the 037 family, as well as DMSO and R848 (n=15) is 
shown. The compounds were tested at four different increasing concentrations, indicated 
by the black triangles. The concentrations are 0.4 µM, 1.2 µM, 3.7 µM, and 11.0 µM. 
The stars indicate statistical significance between the indicated compound over the 
DMSO-treatment, as determined by running a nonparametric Wilcoxon matched-pairs 
rank test for each compound in comparison to the unstimulated condition (DMSO).  
 
Figures 2 and 3 show that at the top two concentrations (3.7 µM and 11.0 µM), certain 
compounds from the 037 family induce TNF and IL-1β production comparable to that 
induced by R848 in adult human whole blood. To determine which compounds were the 
most active, a nonparametric Wilcoxon matched-pairs rank test for each compound in 
comparison to the unstimulated condition (DMSO) was performed. The results of the test 
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indicate that in adult human whole blood, compounds 37.37, FRF-02-116, FRF-02-167, 
FRF-02-171, and FRF-02-175 as well as R848 were most active in terms of TNF 
production, while compounds 37.37, FRF-02-116, FRF-02-118, FRF-02-166, FRF-02-
167, FRF-02-171, and FRF-02-175 as well as R848 were most active in terms of IL-1β 
production. Figures 4 and 5 below will show the induction of TNF and IL-1β in newborn 
human whole blood after stimulation with the compounds of the 037 family, as well as 
DMSO and R848.  
 
	
Figure 4. Lead Candidate Adjuvants Induce TNF Production in Human Newborn 
Whole Blood Assay. The production of TNF in newborn human whole blood after 
stimulation with the compounds of the 037 family, as well as DMSO and R848 (n=7) is 
shown. The compounds were tested at four different increasing concentrations, indicated 
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by the black triangles. The concentrations are 0.4 µM, 1.2 µM, 3.7 µM, and 11.0 µM. 
The stars indicate statistical significance between the indicated compound over the 
DMSO-treatment, as	determined by running a nonparametric Wilcoxon matched-pairs 
rank test for each compound in comparison to the unstimulated condition (DMSO). 
 
	
Figure 5. Lead Candidate Adjuvants Induce IL-1β  Production in Human Newborn 
Whole Blood Assay. The production of IL-1β in newborn human whole blood after 
stimulation with the compounds of the 037 family, as well as DMSO and R848 (n=7) is 
shown. The compounds were tested at four different increasing concentrations, indicated 
by the black triangles. The concentrations are 0.4 µM, 1.2 µM, 3.7 µM, and 11.0 µM. 
The stars indicate statistical significance between the indicated compound over the 
DMSO-treatment, as determined by running a nonparametric Wilcoxon matched-pairs 
rank test for each compound in comparison to the unstimulated condition (DMSO).  	
Figures 4 and 5 also show that at the top two concentrations (3.7 µM and 11.0 µM), 
certain compounds induce TNF and IL-1β production comparable to that produced by 
R848 in newborn human whole blood. Similar to the adult data set, a nonparametric 
Wilcoxon matched-pairs signed rank test for each compound in comparison to the 
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unstimulated condition (DMSO) was performed in order to determine the most active 
compounds.  The most active compounds in terms of TNF production are compounds 
37.37, FRF-02-116, FRF-02-144-3, FRF-02-166, FRF-02-167, and FRF-02-171 as well 
as R848. For IL-1β production in newborns, it was found that compounds 37.37, FRF-02-
116, FRF-02-118, FRF-02-144-3, FRF-02-166, FRF-02-167, FRF-02-169, FRF-02-171, 
and FRF-02-175 as well as R848 were most active. 
The most active lead candidate adjuvants that were determined for both newborns 
and adults are shown in figures 6, 7, 8, and 9 below.   	
	
Figure 6. Comparison of Potency of Lead TNF-Inducing Compounds in Adult 
Human Whole Blood. The concentration-dependent activity of compounds in the 037 
family that were most active at the top two concentrations (3.7 µM and 11.0 µM) in 
inducing TNF production is shown. The compounds are compared to DMSO, which is 
the solvent control (purple line). R848, which is the positive control, is also included.  
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Figure	7. Comparison of Potency of Lead IL-1β-Inducing Compounds in Adult 
Human Whole Blood. The concentration-dependent activity of the compounds in the 
037 family that were most active at the top two concentrations (3.7 µM and 11.0 µM) in 
inducing IL-1β production is shown. The compounds are compared to DMSO, which is 
the solvent control (purple line). R848, which is the positive control, is also included. 
Stars indicate compounds with significantly different curves than DMSO, which is an 
indication of the potency of the compounds compared to DMSO (purple line).  
 
Figures 8 and 9 below will also show a comparison of the most active TNF and IL-1β - 
inducing compounds in newborns that were determined by performing newborn human 
whole blood assays.  	
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Figure 8. Comparison of Potency of Lead TNF-Inducing Compounds in Newborn 
Human Whole Blood. The concentration-dependent activity of the compounds in the 
037 family that were most active at the top two concentrations (3.7 µM and 11.0 µM) in 
inducing TNF production is shown. The compounds are compared to DMSO, which is 
the solvent control (purple line). R848, which is the positive control, is also included. 
Stars indicate compounds with significantly different curves than DMSO, which is an 
indication of the potency of the compounds compared to DMSO (purple line). 
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Figure 9. Comparison of Potency of Lead IL-1β-Inducing Compounds in Newborn 
Human Whole Blood. The concentration-dependent activity of the compounds in the 
037 family that were most active at the top two concentrations (3.7 µM and 11.0 µM) in 
inducing IL-1β production is shown. The compounds are compared to DMSO, which is 
the solvent control (purple line). R848, which is the positive control, is also included. 
Stars indicate compounds with significantly different curves than DMSO, which is an 
indication of the potency of the compounds compared to DMSO (purple line). 
		
The most active compounds were then analyzed using a repeated measure (RM) 2-way 
ANOVA test to evaluate the differences in potency of the compounds. The RM 2-way 
ANOVA looked at the difference of the curves between DMSO (unstimulated condition) 
and the compound in question. The compounds that resulted in a significant difference in 
the curve from DMSO are indicated with stars in Figures 6, 7, 8, and 9.  The difference in 
curves can be used to evaluate differences in potency of the compounds (the more 
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significant the difference in curves from DMSO, the better the compound). The results 
are as follows: for the most active compounds regarding TNF production in adult human 
whole blood, the RM 2-way ANOVA analysis did not generate any significant results. 
However, Figure 6 demonstrates that the curve for R848 appears distinct from that of 
DMSO. The test results could be due to the variation in error bars. For the most active 
compounds regarding IL1β-production in adult human whole blood, R848, FRF-02-171, 
and FRF-02-175 had significantly different curves than DMSO, suggesting there is a 
difference in potency of the compounds in that they induce greater cytokine production 
than DMSO, which is the solvent control. For most active compounds regarding TNF 
production in newborn human whole blood, all the compounds except for R848 had 
significantly different curves than DMSO, suggesting that they are more potent than 
DMSO. However, Figure 8 shows that R848 is visually the most different curve and the 
most active compound; the lack of significance in the ANOVA could be due to the 
variation in error bars. For the most active compounds regarding IL1β production in 
newborn human whole blood, all the compounds had significantly different curves than 
DMSO, suggesting that they are more potent than DMSO.  
The above figures and results demonstrate that the compounds in the 037 family do in 
fact induce TNF and IL1β production, and that certain compounds are more active than 
the others at higher concentrations. The active compounds depend on which cytokine is 
being produced, as well as which age group is being tested.  
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Comparison of TNF and IL-1β  Induction by Lead Adjuvant Candidates 
Between Human Newborns and Adults  
 The following two figures (Figures 10 and 11) will show the direct comparison of 
each compound in human newborn and adult whole blood. The purpose of these figures 
is to show a side-by-side comparison of the activity of these compounds with regards to 
inducing cytokine production in human newborns and adults, and to highlight the 
compounds that result in a significant difference between newborns and adults in terms of 
cytokine production. The compounds that result in a significant difference were 
determined by performing an unpaired nonparametric Mann-Whitney test.    
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A continued
 
Figure 10. Side-by-Side Comparison of TNF-Induction by the Lead Adjuvant 
Candidates in Human Newborn and Adult Whole Blood. The figure illustrates a direct 
comparison of the TNF-inducing abilities of the compounds in the 037 family between 
human newborns and adults. DMSO and R848 comparisons are also shown. Stars 
indicate the compounds that resulted in a significant difference in TNF production 
between newborns and adults. The significant differences were determined by performing 
an unpaired nonparametric Mann-Whitney test.  
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Figure 11. Side-by-Side Comparison of IL-1β-Induction by the Lead Adjuvant 
Candidates in Human Newborn and Adult Whole Blood. The figure illustrates a direct 
comparison of the IL-1β-inducing abilities of the compounds in the 037 family between 
human newborns and adults. DMSO and R848 comparisons are also included. Stars 
indicate the compounds that resulted in a significant difference in IL-1β production 
between newborns and adults. The significant differences were determined by performing 
an unpaired nonparametric Mann-Whitney test.  
 
Newborn Adult 
1
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B FRF-02-166 
Newborn 
Adult 
*
Newborn Adult 
1
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B FRF-02-169 
Newborn 
Adult 
***
Newborn Adult 
1
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B FRF-02-175
Newborn
Adult 
Newborn Adult 
1
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B FRF-02-167
Newborn 
Adult 
**
Newborn Adult 
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B FRF-02-171
Newborn 
Adult 
Newborn Adult 
10
100
1000
10000
IL1B
Co
nc
en
tra
tio
n (
pg
/m
L)
IL1B R848
Newborn
Adult 
* P<0.05
** p<0.01
*** p<0.001
		 31 
	
Figures 10 and 11 illustrate that there are differences in the response to these compounds 
for newborns and adults, with certain compounds resulting in an increased production of 
the cytokines in newborns than compared to adults. The purpose of comparing the solvent 
control (DMSO) for both newborns and adults was to show if there is a difference in the 
immune response between newborns and adults at basal level, which according to Figures 
10 and 11, there does not seem to be a substantial difference. To determine whether or 
not the differences in cytokine production between newborns and adults were 
significantly different after stimulation with these compounds, an unpaired non-
parametric Mann-Whitney test was performed for each of the comparisons. Stars in 
Figures 10 and 11 indicate the compounds that resulted in a significant difference in 
cytokine production between newborns and adults. The results are as follows: For IL1β 
production, compounds 037, FRF-02-116, FRF-02-144-3, FRF-02-166, FRF-02-167, and 
FRF-02-169 resulted in significant differences between newborns and adults. For TNF 
production, compounds FRF-02-144-3, FRF-02-166, FRF-02-167, and FRF-02-169 
resulted in significant differences between newborns and adults.  
Further Characterization of the Cytokine and Chemokine Response of the Lead 
Adjuvant Candidates  	 Lastly, to investigate in further detail the type of response that these compounds 
induce, a 41-plex cytokine multiplex was run on the cytokines and chemokines listed 
earlier. The compounds that were tested in the multiplex in addition to DMSO and R848 
were FRF-02-118, FRF-02-171, and FRF-02-175. These	three compounds were	decided 
		 32 
upon because they seemed to induce cytokine production in both newborns and adults, 
mainly at the highest concentration (11 µM) as seen in Figures 2, 3, 4, and 5. While 41 
different cytokines and chemokines were tested, it was not anticipated that all 41 would 
show up in a whole blood assay, meaning not all 41 would be relevant to the objective of 
this paper. Also, not all of the cyotkines and chemokines resulted in a significant 
concentration, so they were not highlighted. Figure 12 below will illustrate the induction 
for 10 cytokines and chemokines of interest that are important for vaccine development.  
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Figure 12. Comparison of Cytokine and Chemokine Production in Response to 
Stimulation by DMSO, R848, FRF-02-118, FRF-02-171, and FRF-02-175 Between 
Human Adult and Newborn Whole Blood. The proinflammatory/Th1 cytokines (IFN 
alpha 2, IFN gamma, IL-12p70, IL-1 alpha, and IL-12p40) are grouped together. The 
anti-inflammatory/Th2 cytokines (IL-6 and IL-10) are grouped together. The chemokines 
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(CXCL1, CXCL8, and CXCL10) are grouped together. The color indicates the 
concentration of the cytokine/chemokine produced in pg/ml. DMSO is used as the 
unstimulated condition, while R848 is the positive control. 		
In Figure 12, the pro-inflammatory cytokines/Th1 cytkines are grouped next to each other 
(IFN alpha 2, IFN gamma, IL-12p70, IL-1 alpha, and IL-12p40), while the anti-
inflammatory/Th2 cytokines are grouped next to each other (IL-6 and IL-10) (Cavaillon, 
2001). The three chemokines (CXCL1, CXCL8, and CXCL10) are also grouped next to 
each other. According to Figure 12, there does not seem to be a clear distinction between 
the pro-inflammatory/Th1 and anti-inflammatory/Th2 cytokine production in newborns 
and adults. Rather, the differences seem to vary with the specific cytokine as well as the 
age group. Figure 12 illustrates that in adult human whole blood, there was not any 
significant production of the proinflammatory/Th1 cytokines when stimulated with FRF-
02-118, FRF-02-171, and FRF-02-175; however, in human newborn whole blood these 
three compounds induced significant IL-1 alpha production. For the anti-
inflammatory/Th2 cytokines that were tested, adults produced a significant amount of IL-
6 when stimulated with the three compounds, while newborns seemed to produce a 
significant amount of both IL-6 and IL-10 when stimulated with the compounds.  Lastly, 
Figure 12 illustrates that both newborns and adults produce a significant amount of all 
three chemokines in response to stimulation with FRF-02-118, FRF-02-171, and FRF-02-
175. Adults produced a greater amount of CXCL8 in particular, while newborns 
produced a greater amount of CXCL1. However, the newborns also seem to have a 
greater pre-existing amount of the chemokines in whole blood, as indicated by the 
significant concentrations in the solvent control condition (DMSO). 
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DISCUSSION 	 The goal of this study was to test a small molecule library of compounds that was 
determined from earlier experiments to be significant with the potential to act as 
adjuvants in vaccines. One compound in particular, compound 037, was determined to 
produce pro-inflammatory cytokines, specifically TNF, similar to the level produced by 
R848, which is known to have adjuvant activity. After identifying compound 037, 
structural analogues of this compound were purchased and tested for potential adjuvant 
activity as well. It was hypothesized that compound 037 is a possible adjuvant candidate; 
however, the results of this thesis demonstrate that some of the structural analogues are 
better able to induce cytokine production in newborns and adults. The results were 
specific to the cytokine in question, as well as the age group of the blood sample, which 
suggests that these compounds differ in their ability to induce cytokine production and 
are age-specific. The difference in activity for these compounds could possibly be due to 
the structures. While the parent structure is conserved in all 10 compounds, there are 
different functional groups that could contribute to the ability of these compounds to 
induce cytokine production. The parent compound, 037, lacks a trifluoride group; 
however, this trifluoride group is present in many of the compounds that induced greater 
cytokine production than compared to 037. This suggests that this functional group might 
increase the activity of these compounds; however, as mentioned previously, we cannot 
show the structures of the compounds at this time. Another notable feature of the 
cytokine/chemokine multiplex data (Figure 12) was that compounds FRF-02-118, FRF-
02-171, and FRF-02-175 all seemed to induce chemokine production at levels 
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comparable to or even greater than R848, especially in adults. The specific chemokines 
that were analyzed in this paper were C-X-C Motif Chemokine Ligand 1 (CXCL1), 
which is an antimicrobial gene that has a role in inflammation and acts as a chemo-
attractant for neutrophils to the site of infection (“CXCL1 Gene - GeneCards | GROA 
Protein | GROA Antibody,” n.d.). C-X-C Motif Chemokine Ligand 8 (CXCL8) is another 
chemokine that was measured in the multiplex data; it is also a mediator of the 
inflammatory response and also plays a role in guiding neutrophils to the site of infection 
(“CXCL8 Gene - GeneCards | IL8 Protein | IL8 Antibody,” n.d.). The last chemokine that 
was measured is C-X-C Motif Chemokine Ligand 10 (CXCL10), which is an 
antimicrobial gene that stimulates monocytes, induces migration of natural killer cell and 
T-cells, and modulates expression of adhesion molecules (“CXCL10 Gene - GeneCards | 
CXL10 Protein | CXL10 Antibody,” n.d.). The fact that the three compounds from the 
037 family induced increased chemokine production in adults suggests that adjuvant 
activity of these compounds could possibly be due to chemo-attraction of other cell types 
to the site of infection. The newborns did not seem to show a significant increase from 
the unstimulated condition (DMSO), because the unstimulated condition seemed to have 
high pre-existing levels of the chemokines to begin with. This is because human CD4+ T 
cells from preterm and term neonates have the capacity to induce a pro-inflammatory 
response in the form of CXCL8 production (Das et al., 2017). The receptor that these 
compounds bind to are not yet identified, which leads to the question of whether or not 
these compounds are actually TLR7/8 agonists. The chemokine data suggests that these 
compounds could very well activate different pathways and cell types, leading to an 
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inflammatory response. Figure 12 also shows that there is no clear distinction between 
pro-inflammatory and anti-inflammatory cytokine production, in the sense that there is no 
pattern to suggest that stimulation with these compounds induce a greater pro-
inflammatory cytokine production in newborns. Further studies are needed to define the 
cellular and molecular pathways by which these compounds activate human leukocytes.  
Implications for Future Research 	 This project characterized the most active compounds from an already identified 
small molecule library that could potentially act as adjuvants in vaccines to aid in 
enhancing the newborn immune response. Possible next steps would be to look at the 
activity of the parent group and the functional groups, to determine if the functional 
groups play a role in enhancing activity as well as which functional groups can be 
changed to enhance activity. Also, elderly blood samples could be tested to further 
investigate the effects of age on the innate immune response. Further development of 
these candidate adjuvants can enable future age-specific vaccine development.  
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